KRAS and cancer: Here, we analyzed next-generation sequencing (NGS) data from patients with various cancer subtypes to characterize the prevalence of KRASG12C and other KRAS variants, identify associated genomic alterations, and describe the relationship between KRAS mutation status and IO biomarkers, which may provide guidance for future therapeutic strategies.